April DeMore

发表

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors

L. Saltz, N. Raj, M. Capanu, 2022, JCO oncology practice.

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas

N. Raj, P. Munster, L. Fong, 2023, British Journal of Cancer.